NO20081379L - Pankreatinmikropelletkjerner egnet for enterisk belegning - Google Patents

Pankreatinmikropelletkjerner egnet for enterisk belegning

Info

Publication number
NO20081379L
NO20081379L NO20081379A NO20081379A NO20081379L NO 20081379 L NO20081379 L NO 20081379L NO 20081379 A NO20081379 A NO 20081379A NO 20081379 A NO20081379 A NO 20081379A NO 20081379 L NO20081379 L NO 20081379L
Authority
NO
Norway
Prior art keywords
pancreatin
enteric coating
pancreatin micropellet
cores suitable
micropellet cores
Prior art date
Application number
NO20081379A
Other languages
English (en)
Norwegian (no)
Inventor
Claus-Juergen Koelln
George Shlieout
Frithjof Sczesny
Jens Onken
Guido Ruesing
Original Assignee
Abbott Lab Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081379(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab Gmbh filed Critical Abbott Lab Gmbh
Publication of NO20081379L publication Critical patent/NO20081379L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20081379A 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning NO20081379L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (1)

Publication Number Publication Date
NO20081379L true NO20081379L (no) 2008-05-14

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081379A NO20081379L (no) 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning

Country Status (15)

Country Link
EP (1) EP1931317B1 (de)
JP (1) JP5284092B2 (de)
KR (1) KR101302841B1 (de)
AT (1) ATE418329T1 (de)
AU (1) AU2006281415B2 (de)
CA (1) CA2619477C (de)
DE (1) DE602006004471D1 (de)
ES (1) ES2320174T3 (de)
IL (1) IL189457A (de)
MX (1) MX2008001557A (de)
NO (1) NO20081379L (de)
PL (1) PL1931317T3 (de)
PT (1) PT1931317E (de)
RU (1) RU2408364C2 (de)
WO (1) WO2007020260A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
PL1729797T3 (pl) 2004-03-22 2009-02-27 Abbott Laboratories Gmbh Doustne kompozycje farmaceutyczne produktów zawierających lipazę, a zwłaszcza pankreatynę, zawierające środki powierzchniowo czynne
BRPI0614914A2 (pt) 2005-07-29 2011-04-19 Solvay Pharm Gmbh processos para a fabricação de pó de pancreatina esterilizada
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
AR065405A1 (es) 2007-02-20 2009-06-03 Eurand Pharmaceuticals Ltd Composiciones estables de enzimas digestivas
US20110008423A1 (en) * 2008-01-03 2011-01-13 Abbott Products Gmbh Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
EP2373693A4 (de) 2009-01-06 2012-04-25 Curelon Llc Zusammensetzungen und verfahren zur behandlung bzw. prävention von mundinfektionen durch e.coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2440210A4 (de) 2009-06-12 2014-01-29 Meritage Pharma Inc Verfahren zur behandlung von magen-darm-erkrankungen
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2621476B8 (de) 2010-10-01 2020-12-23 Société des Produits Nestlé S.A. Enterale beschichtete pancrelipase-formulierungen mit geringer festigkeit
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
CN103619348B (zh) 2011-04-21 2016-10-26 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
CN103732245B (zh) 2011-08-08 2016-07-06 阿普塔利斯制药有限公司 用于含有消化酶的组合物的溶出度测试的方法
US10350278B2 (en) * 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
EP3157568A1 (de) 2014-06-19 2017-04-26 Aptalis Pharma Limited Verfahren zur entfernung von viralen verunreinigungen aus pankreatischen extrakten
CN107073084B (zh) 2014-11-05 2022-03-25 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
EP3609528A4 (de) 2017-04-10 2020-12-23 Curemark, LLC Zusammensetzungen zur suchtbehandlung
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
UA129226C2 (uk) * 2020-06-10 2025-02-12 Кусум Хелтхкер Пвт. Лтд. Фармацевтична композиція панкреатину
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR20250116893A (ko) 2024-01-26 2025-08-04 황준영 판크레아틴 함유 속방성 장용코팅 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
NZ514826A (en) * 1999-03-17 2003-08-29 Solvay Pharm Gmbh Medicinal product for the treatment of diabetes
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
WO2007020260A3 (en) 2007-05-10
JP2009504710A (ja) 2009-02-05
EP1931317A2 (de) 2008-06-18
PL1931317T3 (pl) 2009-06-30
MX2008001557A (es) 2008-02-15
HK1119559A1 (en) 2009-03-13
PT1931317E (pt) 2009-02-02
RU2408364C2 (ru) 2011-01-10
KR101302841B1 (ko) 2013-09-02
ATE418329T1 (de) 2009-01-15
KR20080034516A (ko) 2008-04-21
WO2007020260A2 (en) 2007-02-22
JP5284092B2 (ja) 2013-09-11
CA2619477A1 (en) 2007-02-22
AU2006281415B2 (en) 2012-01-19
RU2008109651A (ru) 2009-09-27
IL189457A0 (en) 2008-06-05
ES2320174T3 (es) 2009-05-19
IL189457A (en) 2014-05-28
DE602006004471D1 (de) 2009-02-05
EP1931317B1 (de) 2008-12-24
AU2006281415A1 (en) 2007-02-22
CA2619477C (en) 2015-05-26

Similar Documents

Publication Publication Date Title
NO20081379L (no) Pankreatinmikropelletkjerner egnet for enterisk belegning
WO2010014949A3 (en) Compositions comprising hepatocyte-like cells and uses thereof
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
WO2011044089A3 (en) Methods of treating depression and other related diseases
NO20090046L (no) Preparater og fremgangsmater for modulering av vaskulaer utvikling
NO20090968L (no) Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
EP2331562A4 (de) Peptide mit einem epitop einer domäne des faktor-h-bindenden proteins und anwendungsverfahren
EP2280720A4 (de) Kollagenbindende synthetische peptidoglykane, herstellung und anwendungsverfahren
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2008120105A3 (en) Pharmaceutical platform technology for the development of natural products
IL161903A0 (en) Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
TW200602089A (en) Sugar coatings and methods therefor
WO2007109605A3 (en) Pharmaceutical compositions
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EP2264048A4 (de) Peptid-des-[asp1]-[ala1]-angiotensin-(1-7)-agonist und pharmazeutische verbindungen zur behandlung von krankheiten
WO2009067543A3 (en) Treatment of histone deacetylase mediated disorders
DK2151235T3 (da) Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
EP1970099A3 (de) Verfahren zum Glätten des Haars
EP3735587A4 (de) Synchronisierter zellzyklus-genexpressionstest für morbus alzheimer und verwandte therapeutische verfahren
MA28563B1 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation
WO2008121963A3 (en) Compositions and methods for gene silencing
ZA200808621B (en) Use of non-hydroxide bases with heat for relaxing or straightening hair
UA89102C2 (ru) Ядра микропеллета панреатита, пригодные для нанесеня энтеросолюбильного покрытия

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE